By Gilang Cahya 
In a groundbreaking discovery that reframes our understanding of cancer’s adaptability, researchers at University College London (UCL) and University Medical Center Utrecht have identified a remarkable phenomenon: bowel cancer cells possess the ability to strategically regulate their growth by manipulating genetic "on-off" switches, thereby maximizing their chances of survival and progression. This revelation, published in the esteemed journal Nature Genetics, challenges the long-held belief that the number of genetic mutations within a cancer cell is solely a matter of random chance. Instead, it points towards a sophisticated, almost conscious, evolutionary strategy employed by malignant tumors.
The Adaptive Nature of Cancer: A New Paradigm
For decades, the scientific community has grappled with the complex genetic landscape of cancer. While it is understood that cancer arises from accumulated DNA mutations, the precise control and purpose behind these alterations have remained largely elusive. The new study introduces the concept of an "evolutionary balancing act," where cancer cells actively manage their mutational burden. This is achieved through the dynamic manipulation of DNA repair genes, which act as critical genetic switches. These switches can be activated or deactivated, effectively "taking the brakes off" tumor growth when a surge in mutations is beneficial, or "putting the brakes back on" when a slower, more controlled accumulation of genetic changes is advantageous for survival and immune evasion.
The implications of this discovery are profound, particularly for the field of personalized cancer medicine. Researchers suggest that understanding these genetic switches could provide a novel method for gauging the aggressiveness of an individual’s cancer. This, in turn, would enable clinicians to tailor treatment strategies with unprecedented precision, ensuring patients receive the most effective interventions based on their tumor’s specific adaptive mechanisms.
Understanding Cancer’s Genetic Foundation
Cancer, at its core, is a disease driven by mutations in our DNA. Throughout our lives, DNA damage is a constant threat, stemming from both natural cellular processes and external environmental factors. Our cells have evolved intricate mechanisms to protect the integrity of our genetic code, employing sophisticated repair pathways. However, when mutations accumulate in critical genes that control cell growth and division, the stage is set for tumor development.
Bowel cancer, also known as colorectal cancer, is a significant global health concern. In the UK, it stands as the fourth most common cancer, with an estimated 42,900 new cases diagnosed annually. While it predominantly affects older individuals, a worrying trend of increasing incidence among those under 50 has been observed in recent decades, prompting intensified research into its underlying causes and mechanisms.
DNA Repair Disruption: A Double-Edged Sword
A substantial contributor to increased cancer risk is the disruption of DNA repair mechanisms. Approximately 20% of bowel cancers, classified as mismatch repair deficient (MMRd) cancers, are directly linked to mutations in specific DNA repair genes. While disabling these repair mechanisms can facilitate tumor development by allowing mutations to accumulate, this unrestrained mutational activity is not without its drawbacks for the cancer cell. Each new mutation increases the likelihood that the body’s immune system will recognize the tumor as foreign and initiate an attack.
The Immune System’s Dilemma and Cancer’s Strategy
Dr. Marnix Jansen, a senior author of the study from the UCL Cancer Institute and UCLH, elaborated on this complex interplay. "Cancer cells need to acquire certain mutations to circumvent mechanisms that preserve our genetic code," he explained. "But if a cancer cell acquires too many mutations, it is more likely to attract the attention of the immune system, because it’s so different from a normal cell. We predicted that understanding how tumours exploit faulty DNA repair to drive tumour growth – whilst simultaneously avoiding immune detection – might help explain why the immune system sometimes fails to control cancer development."
This prediction formed the cornerstone of the research, leading the team to investigate the intricate relationship between the mutational load in tumors and the status of DNA repair genes.
Unraveling the Genetic Switches: A Chronology of Discovery
The research journey began with a meticulous analysis of whole genome sequences from 217 MMRd bowel cancer samples, sourced from the 100,000 Genomes Project database. This extensive dataset provided the raw material for identifying potential correlations between the total number of mutations observed in cancer cells and specific genetic alterations within key DNA repair genes.
The team’s rigorous investigation pinpointed a strong and consistent correlation between mutations in the MSH3 and MSH6 genes – crucial components of the DNA mismatch repair system – and an exceptionally high volume of mutations across the cancer genome. This finding provided the initial evidence for the hypothesis that these specific DNA repair gene mutations might act as a regulatory mechanism, controlling the rate at which new mutations arise.
To validate this groundbreaking theory, the researchers moved beyond genomic analysis and employed sophisticated laboratory models. They utilized complex cell cultures known as organoids, which are essentially miniature, three-dimensional versions of tumors grown directly from patient samples. These organoids allowed the scientists to observe the functional consequences of DNA repair gene mutations in a controlled environment, confirming that these ‘flip-flop’ mutations indeed played a pivotal role in modulating cancer mutation rates.
Dr. Suzanne van der Horst from the University Medical Center Utrecht described the pivotal insight: "Our study reveals that DNA repair mutations in the MSH3 and MSH6 genes act as a genetic switch that cancers exploit to navigate an evolutionary balancing act. On one hand, these tumours roll the dice by turning off DNA repair to escape the body’s defence mechanisms. While this unrestrained mutation rate kills many cancer cells, it also produces a few ‘winners’ that fuel tumour development."
However, the narrative of cancer’s adaptation did not end with uncontrolled mutation. Dr. van der Horst continued, "The really interesting finding from our research is what happens afterwards. It seems the cancer turns the DNA repair switch back on to protect the parts of the genome that they too need to survive and to avoid attracting the attention of the immune system. This is the first time that we’ve seen a mutation that can be created and repaired over and over again, adding it or deleting it from the cancer’s genetic code as required."
The Mechanism: Repetitive DNA and Cellular Errors
The specific DNA repair mutations implicated in this phenomenon occur within repetitive stretches of DNA. These regions, characterized by the repeated sequence of a single DNA letter (A, T, C, or G), are found throughout the human genome. During cell division, a common occurrence is the introduction of minor copying errors in these repetitive sequences, such as inadvertently changing eight consecutive ‘C’s into seven. Such small alterations can significantly disrupt gene function, including the function of DNA repair genes.
Dr. Hamzeh Kayhanian, the study’s first author from the UCL Cancer Institute and UCLH, emphasized the paradigm shift this discovery represents. "The degree of genetic disarray in a cancer was previously thought to be purely down to chance accumulation of mutations over many years," he stated. "Our work shows that cancer cells covertly repurpose these repetitive tracts in our DNA as evolutionary switches to fine-tune how rapidly mutations accumulate in tumour cells."
Parallels with Bacterial Evolution
Intriguingly, the researchers noted a striking similarity between this mechanism and evolutionary strategies observed in bacteria. "Interestingly, this evolutionary mechanism had previously been found as a key driver of bacterial treatment resistance in patients treated with antibiotics," Dr. Kayhanian added. "Like cancer cells, bacteria have evolved genetic switches which increase mutational fuel when rapid evolution is key, for example when confronted with antibiotics. Our work thus further emphasises similarities between evolution of ancient bacteria and human tumour cells, a major area of active cancer research." This connection underscores the fundamental principles of evolution that govern life at its most basic levels, from single-celled organisms to complex human tumors.
Implications for Treatment and Future Research
The immediate implications of this research lie in its potential to revolutionize cancer treatment strategies. By identifying these genetic switches, clinicians could gain a deeper insight into a tumor’s propensity for rapid adaptation and resistance to therapy. Tumors that have actively switched off DNA repair mechanisms, for instance, may be more likely to evolve quickly and evade treatment, particularly immunotherapies, which are designed to exploit highly mutated tumors. Understanding this adaptive capacity could allow for more aggressive and targeted interventions, potentially improving patient outcomes.
A follow-up study is already in motion, aiming to investigate the behavior of these DNA repair switches in patients undergoing cancer treatment. This will provide crucial real-world data on how these adaptive mechanisms respond to therapeutic pressures.
Dr. Hugo Snippert, another senior author from the University Medical Center Utrecht, expressed optimism for future therapeutic development. "Overall our research shows that mutation rate is adaptable in tumours and facilitates their quest to obtain optimal evolutionary fitness," he said. "New drugs might look to disable this switch to drive effective immune recognition and, hopefully, produce better treatment outcomes for affected patients."
Funding and Support for Cancer Research
This vital research was made possible through the generous support of several esteemed organizations, including grants from Cancer Research UK, the Rosetrees Trust, and Bowel Research UK.
Georgia Sturt, Research and Grants Manager at Bowel Research UK, highlighted the significance of these findings. "Cancer’s evasion of immune system destruction is a key element of its ability to grow and spread," she commented. "Understanding exactly how bowel cancers do this is crucial to optimising treatment for patients. Bowel Research UK are delighted that our funding has contributed to producing this exciting new data, and we look forward to seeing how these discoveries could change treatments for future patients."
The discovery of these genetic on-off switches in bowel cancer cells marks a significant leap forward in our comprehension of cancer’s remarkable resilience and adaptability. It opens new avenues for diagnostic tools and therapeutic interventions, offering renewed hope for improved patient outcomes in the ongoing battle against this formidable disease.
